Table 3.
Safety findings: non-hematologic, treatment-related adverse events (AEs) reported by at least 15% of patients or of clinical interest, and hematologic abnormalities
| Number of patients, N = 32 n (%) | ||
|---|---|---|
| Totala | Grade 3/4a | |
| Non-hematologic AEs | ||
| Fatigue | 44 (73) | 8 (13) |
| Diarrheab | 37 (62) | 3 (5) |
| Hypertensionb | 35 (48) | 1 (2) |
| Nausea | 29 (48) | 1 (2) |
| Transaminitis | 21 (35) | 10 (17) |
| Hematologic abnormalitiesc | ||
| Anemia | 13 (22) | 0 |
| Thrombocytopenia | 4 (7) | 0 |
| Neutropenia | 18 (30) | 9 (15) |
aNational Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0
bNot otherwise specified
cBased on laboratory data